Share

April 2019; 9 (2) Research

Predictors of dementia misclassification when using brief cognitive assessments

Janice M. Ranson, Elżbieta Kuźma, William Hamilton, Graciela Muniz-Terrera, Kenneth M. Langa, David J. Llewellyn
First published November 28, 2018, DOI: https://doi.org/10.1212/CPJ.0000000000000566
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3062

Share

Article Information

vol. 9 no. 2 109-117
DOI: 
https://doi.org/10.1212/CPJ.0000000000000566
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received May 30, 2018
  • Accepted September 17, 2018
  • First Published November 28, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Janice M. Ranson, MSc,
    2. Elżbieta Kuźma, PhD,
    3. William Hamilton, MD,
    4. Graciela Muniz-Terrera, PhD,
    5. Kenneth M. Langa, MD, PhD and
    6. David J. Llewellyn, PhD
  1. Janice M. Ranson, MSc,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Elżbieta Kuźma, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)Halpin Trust(2) James Tudor Foundation(3) Wellcome Trust ISSF Seed Corn Fund(4) Mary Kinross Charitable Trust

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. William Hamilton, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Family Practice (Oxford), Associate Editor, since 2007

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, Department of Health. ?4,997,576.00 [co- applicant, and early diagnosis lead] 2018-2023. 2.Understanding the effectiveness, cost-effectiveness and current use of cancer diagnostic tools to aid decision- making in primary care. HTA ?240,800. [co-applicant] 2017-8 3. 'WICKED? (Wales Interventions and Cancer Knowledge about Early Diagnosis): The development and evaluation of primary care interventions to expedite the diagnosis of symptomatic cancer in Wales. Welsh Govt ?800,000, 2016-8. [co-applicant] 4. Clinical and cost effectiveness of progressive exercise compared to best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders: a 2x2 factorial randomized controlled trial (GRASP). NIHR HTA ?1,228,000 2016-9.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. What is the clinical-effectiveness and cost-effectiveness of embedded risk-of-cancer assessment of patients in primary care; the ERICA trial. W Hamilton, M Pitt, Anne Spencer, John Campbell, Rod Taylor, G Abel & F Warren, and S Dean. ?2.75m Philanthropic donation to University of Exeter, D and M Gillings, 2018-2020 [principal applicant] 2.Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models. Baldwin, D, O?Dowd, E, Hubbard, R, de Koning, H, Field, J, Hamilton, W, Callister, M, ten Haaf, K, Janes, S. CRUK. 2018-2021, ?352,945. [co-applicant] 3. Enhancing the diagnostic pathway for dementia: The DECODE Project. Llewellyn D,Ballard, C, Campbell, J, Hamilton W, Dean D, Kuzma, E, Moore, S, Warren, F, Lang I. The Halpin Trust. ?123,558. 2018-2020. 4. Guideline discordant diagnostic care: when do primary care referrals not reflect guidelines for suspected cancer. Abel G, Lyratzopoulos, G, Campbell, J, Hamilton W. CRUK, ?117.089. 2018-9. [co-applicant] 5. CanTest- Cancer diagnostic testing in primary care: a paradigm shift for cancer diagnosis. Hamilton W, Walter F (co-PIs), Johnson, M, Singh, H, Lyratzopoulos, G, Abel, G, Spencer, A, Thompson, M, Sutton, S, Rubin, G, Neal R, Vedsted, P, Emery J. CRUK Catalyst Award, ?4,834,829. 2017- 22. [co-PI]

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Graciela Muniz-Terrera, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Kenneth M. Langa, MD, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. University of Pennsylvania, honorarium for lecture

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIA U01 AG009740, Co-I, 2007-2018;

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. David J. Llewellyn, PhD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Roche, conference travel, (2) DSM, workshop travel and speaker honorarium.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Mary Kinross Charitable Trust, (2) Alzheimer?s Society, (3) U.S. National Institute on Aging, (4) Wellcome Trust Institutional Strategic Support Award (internal), (5) Health Foundation, (6) Halpin Trust, (7) James Tudor Foundation, (8) National Institute on Aging (R01 AG055654-01A1), (9) JP Moulton Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the University of Exeter Medical School (J.M.R., E.K., W.H., D.J.L.); Centre for Dementia Prevention, University of Edinburgh (G.M.-T.), United Kingdom; The Alan Turing Institute (D.J.L.), London, United Kingdom; and Medical School (K.M.L.), Institute for Social Research, Institute for Healthcare Policy and Innovation, Veterans Affairs Ann Arbor Healthcare System, University of Michigan.
  1. Correspondence
    Dr. Llewellyn david.llewellyn{at}exeter.ac.uk
View Full Text

Article usage

Article usage: November 2018 to May 2020

AbstractFullPdfSource
Nov 201817650260Highwire
Dec 2018424801343Highwire
Jan 201916590319Highwire
Feb 201910800239Highwire
Mar 20196900141Highwire
Apr 2019315667179Highwire
May 201948710163Highwire
Jun 201933467116Highwire
Jul 20192039555Highwire
Aug 20191422452Highwire
Sep 20192320846Highwire
Oct 20192825375Highwire
Nov 201912515559Highwire
Dec 201924436Highwire
Jan 202023513Highwire
Feb 202028422Highwire
Mar 202024532Highwire
Apr 202029201Highwire
May 202038721Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on The Nerve!

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate The Nerve! Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me